141200-24-0
141200-24-0 structure
- Name: Darglitazone
- Chemical Name: 5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione
- CAS Number: 141200-24-0
- Molecular Formula: C23H20N2O4S
- Molecular Weight: 420.48100
- Catalog: Signaling Pathways Cell Cycle/DNA Damage PPAR
- Create Date: 2017-05-29 21:12:41
- Modify Date: 2024-01-08 16:49:30
-
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research[1].
| Name | 5-[[4-[3-(5-methyl-2-phenyl-1,3-oxazol-4-yl)propanoyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
|---|---|
| Synonyms |
5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]-2,4-thiazolidinedione
Darglitazone 5-[4-[3-(2-phenyl-5-methyl-4-oxazolyl)propionyl]benzyl]thiazolidine-2,4-dione 5-<4-<3-(5-methyl-2-phenyl-4-oxazolyl)propionyl>-benzyl>thiazolidine-2,4-dione Darglitazone [INN] [3H]Darglitazone 5-[4-[3-(5-methyl-2-phenyloxazol-4-yl)propionyl]benzyl]-thiazolidine-2,4-dione UNII-AVP9C03Z3K |
| Description | Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research[1]. |
|---|---|
| Related Catalog | |
| Target |
PPAR-γ |
| In Vitro | In cell lines representing white (3T3-L1 and 3T3-F442A) and brown (HIB-1B) adipose tissues and skeletal muscle (L6), within 4 h of exposing these cells to 30 μM Darglitazone, there is an increase in uncoupling protein 2 (UCP2) mRNA which reached a plateau of 5-10 times the basal in about 8 h. Darglitazone can stimulate the expression of UCP2 gene probably via PPAR-γ[2]. |
| In Vivo | Darglitazone treatment restores euglycemia and normalized elevated corticosterone, triglycerides, and very-low-density lipoprotein levels. Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24 h of recovery. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult[1]. Animal Model: Male diabetic ob/ob mice[1] Dosage: 1 mg/kg Administration: Oral administration; daily; for 7 days Result: Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice. |
| References |
| Molecular Formula | C23H20N2O4S |
|---|---|
| Molecular Weight | 420.48100 |
| Exact Mass | 420.11400 |
| PSA | 118.06000 |
| LogP | 4.63550 |
| Storage condition | -20℃ |
| Precursor 1 | |
|---|---|
| DownStream 0 | |